In treatment aspect, recombinant human anti‐complement C5 monoclonal antibodies, new complement inhibitors, and allogeneic hematopoietic stem cell transplantation have made great progress in the field of PNH therapy.4, 5, 6, 7, 8 China as a developing country, eculizumab is not yet available in China, and we have no experience with eculizumab, so the traditional treatment of PNH is aimed at protecting PNH clone, reducing complement attack and destruction, and alleviating hemolysis. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.